Loerop James 4

What Happened

• James Loerop, Chief Business Officer of Aclaris Therapeutics (ACRS), had 20,875 restricted stock units (RSUs convert/derivative) settle on February 3, 2026. To cover tax withholding, 5,937 of those shares were withheld at $3.47 per share, totaling $20,601. Net shares received from this vesting event were 14,938 (20,875 vested − 5,937 withheld).
• This was a vesting/settlement of RSUs (routine compensation event), not an open-market purchase or discretionary sale.

Key Details

• Transaction date: 2026-02-03; Filing date (Form 4): 2026-02-05 (timely).
• Reported entries: conversion/exercise of derivative (code M) for 20,875 shares; tax withholding (code F) of 5,937 shares at $3.47/share for $20,601.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes: F1 = each RSU equals a right to one share; F2 = issuer withheld shares to satisfy tax withholding; F3 = these RSUs vest in four equal annual installments starting Feb 3, 2025 (this represents one installment).
• Filing shows a standard "sell-to-cover" withholding on RSU settlement rather than a market sale.

Context

• This is a routine equity compensation vesting event. The key takeaway for investors is that shares were issued through RSU settlement and some were withheld to pay taxes; it is not a signal of a discretionary insider sale or purchase.